Mirodenafil Overview
Mirodenafil is a synthetic small-molecule phosphodiesterase-5 (PDE5) inhibitor originally developed for investigation of nitric oxide–mediated vasodilation pathways. In laboratory research, it is studied for its selective inhibition of PDE5, the enzyme responsible for degradation of cyclic guanosine monophosphate (cGMP) in smooth muscle tissue.
Mirodenafil is structurally related to other PDE5 inhibitors but exhibits a distinct heterocyclic scaffold and binding profile, making it useful for comparative PDE5 structure–activity and signaling studies.
Mirodenafil is not approved for human or veterinary use in this context and is supplied strictly for laboratory and analytical research purposes.
Mechanism of Action
Mirodenafil functions as a selective PDE5 inhibitor. In research models, inhibition of PDE5 leads to:
-
Increased intracellular cGMP levels
-
Enhanced nitric oxide–mediated signaling
-
Relaxation of vascular smooth muscle
-
Modulation of endothelial and hemodynamic pathways
Because PDE5 is highly expressed in vascular smooth muscle, mirodenafil is commonly examined in studies focused on NO–cGMP signaling cascades and comparative PDE5 pharmacology.
Chemical Structure
Chemical Name:
5-Ethyl-2-{5-[4-(2-hydroxyethyl)piperazin-1-ylsulfonyl]-2-propoxyphenyl}-7-propyl-3,5-dihydro-4H-pyrazolo[4,3-d]pyrimidin-4-one
Synonyms:
Mirodenafil, SK-3530
Molecular Formula:
C₂₃H₃₂N₆O₄S₂
Molecular Weight:
516.66 g/mol
CAS Number:
862507-23-1
Structural Description:
Mirodenafil is a heterocyclic sulfonamide-containing small molecule featuring a pyrazolopyrimidinone core. This scaffold enables selective binding to the PDE5 catalytic site and distinguishes mirodenafil from other PDE5 inhibitors in comparative pharmacological research. Structural identification and molecular data are available via PubChem.
Physical and Chemical Properties
-
Appearance: White to off-white crystalline powder
-
Solubility: Poor aqueous solubility; soluble in common organic solvents
-
Stability: Stable under dry, cool, and light-protected storage conditions
Research Focus Areas
Mirodenafil is commonly examined in laboratory research related to:
-
Phosphodiesterase-5 (PDE5) inhibition
-
Nitric oxide–cGMP signaling pathways
-
Vascular smooth muscle and endothelial research
-
Comparative PDE5 inhibitor structure–activity studies
Research Use Disclaimer
Mirodenafil is intended for research use only.
Not for human consumption, therapeutic use, or diagnostic application. All handling and use must comply with applicable laws, regulations, and laboratory safety standards.
Summary
Mirodenafil is a selective PDE5 inhibitor with verified chemical identifiers:
-
CAS: 862189-95-5
-
Molecular Formula: C₂₆H₃₇N₅O₅S
-
Molecular Weight: 531.67 g/mol
Its distinct heterocyclic structure and selective PDE5 activity make it a valuable research compound for studies of nitric oxide signaling, vascular biology, and comparative phosphodiesterase pharmacology.
| CAS Number | 862189-95-5 |
| Other Names | Mirodenafil Dihydrochloride |
| IUPAC Name | 5-ethyl-2-[5-[4-(2-hydroxyethyl)piperazin-1-yl]sulfonyl-2-propoxyphenyl]-7-propyl-3H-pyrrolo[3,2-d]pyrimidin-4-one |
| Molecular Formula | C₂₆H₃₇N₅O₅S |
| Molecular Weight | 531,666 g/mol |
| Dry-Fill Capsule Concentration | 50mg |
| Liquid Concentration And Solution | 50mg/ml (DMSO, PEG400) |
